Cognition After Lowering LDL-Cholesterol With Evolocumab.

Baris Gencer,François Mach,Jianping Guo,KyungAh Im,Andrea Ruzza,Huei Wang,Christopher E Kurtz,Terje Rolf Pedersen,Anthony C Keech,Brian R Ott,Marc S Sabatine,Robert P Giugliano

Journal of the American College of Cardiology（2020）

引用 59|浏览70

暂无评分

摘要

The addition of evolocumab to maximally tolerated statin therapy had no impact on patient-reported cognition after an average of 2.2 years of treatment, even among patients who achieved LDL-C <20 mg/dl.

查看译文

关键词

cholesterol,cognition,lipid-lowering therapies,PCSK9 inhibitor,safety,statin

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要